{
    "2018-11-15": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Novartis launches third-to-market Remicade copy in Germany",
                "features": {
                    "keywords": [
                        "Novartis",
                        "launches",
                        "Remicade",
                        "Germany"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2018-03-16",
                "original_text": "The Zacks Analyst Blog Highlights: Chevron, Novartis, Qualcomm, TJX and Deere",
                "features": {
                    "keywords": [
                        "Zacks",
                        "Analyst",
                        "Blog",
                        "Chevron",
                        "Novartis",
                        "Qualcomm",
                        "TJX",
                        "Deere"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "diverse"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-17",
                "original_text": "Novartis 'completely committed' to Sandoz, has no split-off plan",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Sandoz",
                        "committed",
                        "split-off"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2018-03-18",
                "original_text": "Novartis says 'completely committed' to Sandoz, not planning split-off",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Sandoz",
                        "committed",
                        "split-off"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}